Member Info for Laura2022

At present

Some companies have done 1000% this last 3mths ( CPAI CLAI SCE)

PYC has won £400,000 of new orders in the last 3mths alone , has raised £500,000 cash just 3mths ago and it's partners with some of the largest global companies (see KingHomer posts last night about one client callee Servier)

And we having precision dosing software that If Intergrayed into NHS or into global platforms like DoseMeRx it could be worthillions

Good morning Burt and OSD

A.i i medicine

PYC are at forefront of A.I as are their clients

500,000 block buys

10% up and still only £1.3mln cap

Harschris

TommyD25 aka Mainman25 aka Santa2024 aka Neil777 does this alot

He's a multi ID disruption

Report to

Info@lse.co.uk

The buy limits had gone down to just about 300-400k into close yesterday

This was from KingHomerJ last month

Dosing Tool Valuation

2025 09:39

The Dosing tool currently in Trial with the NHS Blackpool & Dosemerx is huge for PYC - This trial is due to end in October...

Company Maker......

Estimated Market Size & Tool Value Potential

1. Addressable Market:

o The global precision oncology market is projected to exceed £80 billion by 2030.

o GCSF-related neutropenia management alone represents a multi-billion-dollar submarket within oncology care.

o If Physiomics targets just 1% of high-risk chemotherapy patients in the UK, EU, and US (~1 million annually), and charges:

 £100–£500 per dosing license per patient, the potential annual revenue could be:

 £100M to £500M with adoption.

2. Conservative Valuation Estimate - Based on early-stage rollout and realistic adoption curves:

o Short-term: £500K–£2M revenue potential

o Mid-term £5M–£20M if integrated into mainstream platforms like DoseMeRx, adopted by NHS trusts, or licensed globally

o Exit/Acquisition Scenario: If successful, the tool and IP could attract acquisition interest at multi revenue multiples, yielding a £250M–£500M+ valuation

Explain the large buy last night

Decent results

Operational highlights

·   £5.15m gross proceeds raised during the year; the majority (£4.25m gross) raised in February 2025.

·   Cash runway extended from Q4 2025 to Q4 2026 - orexin-1 antagonist* (Ox-1) programme now funded to clinical readiness

·   TheraCryf in top 20% of European listed biotech companies by duration of cash runway.

·   Seasoned, listed company biotech executive Dr Alastair Smith welcomed as new Chair in February 2025, following the passing of previous Chair, Dr Sue Foden.

·   Completion of the acquisition of Chronos Therapeutics Ltd in April 2024, with the enlarged Group changing its name to TheraCryf. Integration complete during the reporting period.

·   Refocus of strategy with prioritisation of research on brain disorders and acceleration of acquired Ox-1 programme in addiction as key value driver.

·   European (PCT) patent granted in December 2024 for Ox-1, giving protection until 2038, complementing previously granted US patent providing protection in the US until 2039.

·   Publication of SFX-1 Phase 1 volunteer study in peer reviewed journal - most comprehensive evaluation of sulforaphane pharmacokinetics yet.

·   Completion of SFX-01 in vitro work by Erasmus Medical Centre Rotterdam NL, as part of a grant funded study in glioblastoma, start of in vivo pre-clinical work.

·   Constructive and amicable discussions continuing towards resolution of dispute with partner Stalicla SA.

With only 29mln shares and 50% held by funds it all depends on what happens with the Tr1

I'm still watching

https://eagleeye.com/investors/shareholder-centre#aim-rule-26

Sounds fun Burt

Thanks for your reply/clarification Burt

Be good if you were to decide to go about 5%

Thanks for that KingH

Kinghomerj

Do you think we will get further contracts from Servier ?

I've just googled them now and they're a very large company

Lse will remove his latest re incarnation (5th ID in 2025) only if people report the post.voa the report button

AND follow up with a quick email to

Info@lse.co.uk

Burt777

Good evening

0.5p is only the late Feb placing price, since when we've had 3 peer reviews and 5 contracts

I'm hoping for alot more than 1.5p let alone 0.5p

TommyD25

Posted in: EYE

Posts: 465

Earl9er this morning

Price: 218.00

No Opinion

£2.20p about to blow and £2.30p nextToday 12:03

Buy after buy at £2.20

This has hit the bottom and no suprise with how good the financials are.. despite that contract loss

Osb

Hello, just seemed the buying amounts were cut drastically this afternoon compared to this morning

Are you able to ger any more than 200,000 shares here ?

No, not seen them for a week or so

Do you know anything ( fonzl

Hardly any shares available at 0 42p jvip